CVS Health (CVS) Stock Price, Fundamentals & Analysis

What CVS does

CVS Health (CVS) provides health solutions in the United States. Its Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products, including medical, pharmacy, dental, and behavioral health plans, as well as Medicare Advantage, Medicare Supplement, prescription drug plans (PDPs), and Medicaid health care management services. The Health Services segment provides pharmacy benefit management solutions such as plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, and medical spend management services.

Key numbers explained

• 85.86 USD is the latest price for CVS stock, representing the most recent trade on the US market.
• The trailing P/E ratio of 22.7 shows how much investors pay per dollar of the last 12 months' earnings; a lower forward P/E ratio of 10.1 reflects expected future earnings.
• The dividend yield of 3.05% indicates the annual cash return relative to the share price, paid out of 70% of earnings.
• The beta of 0.58 suggests the stock tends to move less than the overall market, which is typical for large healthcare companies.
• 109.81B USD is the market capitalisation, the total value of all outstanding shares.
• 412.64B USD in trailing 12-month revenue and 7.1% year-over-year growth show the scale and top-line expansion of the business.
• The 52-week price range of 69.51 – 110.68 and a 14% price change over the last year illustrate recent volatility and medium-term performance.
• CVS is part of the S&P 500, and investors often compare it with peers such as AbbVie (ABBV) or HCA Healthcare (HCA).

Recent news

Recent headlines include a question about whether UnitedHealth named the fix before its stock ran, a reminder from CVS Health that vaccines are available statewide in Tennessee, and the launch of a national "Wear Your HeART" bandage art contest. Other stories highlight what strengthened CVS in Q2, suggest the stock may be undervalued despite an oncology authorisation expansion, and ask whether UNH stock can keep growing earnings while its sales stall.

What to watch

For a stock like CVS, investors typically monitor health policy changes, insurance enrolment trends, pharmacy benefit contract renewals, and prescription drug pricing developments. Regulatory decisions on Medicare and Medicaid, as well as broader interest rate moves, can also affect healthcare companies. Earnings reports, such as the upcoming release on 28 oct. 2026, often bring updates on revenue, margins, and guidance.